In this study, CHX chase experiments indicated that the half-life of MCL-1 protein in HCC cells was longer in the bilirubin and sorafenib co-treatment group than in the group treated with sorafenib alone. This evidence concerns the gene MCL1 and hepatocellular carcinoma.